CA-CEPTON-TECHNOLOGIES
11.11.2021 15:02:12 CET | Business Wire | Press release
Cepton Technologies, Inc. announced today that it has been named a CES® 2022 Innovation Awards Honoree in the Vehicle Intelligence & Transportation category for its Nova lidar , a miniature, wide field of view lidar sensor for near-range applications. The announcement was made ahead of CES 2022 , a global consumer electronics and consumer technology trade show that will be held from January 5-8 in Las Vegas, NV and digitally.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211111005540/en/
The CES Innovation Awards program, owned and produced by the Consumer Technology Association (CTA)® , is an annual competition honoring outstanding design and engineering in 27 consumer technology product categories. An elite panel of industry expert judges , including members of the media, designers, engineers and more, reviewed submissions based on innovation, engineering and functionality, aesthetic and design. The Nova lidar has been selected among a record high number of submissions to this year’s program, signifying the weight of Nova’s technology and design value for the automotive market.
Nova features a miniature form factor and a wide field of view, making it ideally suited for seamless integration into modern vehicles. With a target volume price point under $100, Nova sets a worldwide benchmark with its unprecedented combination of compactness, field of view coverage and targeted affordability.
Nova is designed to help minimize perception blind spots to enhance advanced driver assistant systems (ADAS) and autonomous driving (AD) capabilities.
It aims to address major gaps in proximity detection of objects with current sensor technologies such as cameras, radars and ultrasonic sensors. Powered by Cepton’s patented Micro Motion Technology (MMT® ) , Nova enables high-resolution 3D imaging to accurately detect small children, on-road objects, protrusions and road edges etc. to help increase vehicle safety and enable a higher level of autonomy. Compared to some other near-range lidars , Nova achieves a higher field of view in both horizontal (120°) and vertical (60°) directions with significantly lower size, power and weight.
Benefiting from the maturity of MMT and Cepton’s proprietary lidar engine ASIC for advanced signal processing, Nova is built to meet the stringent requirements of the automotive industry. An automotive-grade lidar , it supports ASIL-B functional safety and consumes <3.5 W (typical power). Nova can be elegantly embedded all around an automobile to provide a complete 360° view of a vehicle’s immediate surroundings, without disrupting the vehicle’s design aesthetics.
In addition to automotive applications, Nova can also enable autonomous robotics and ground vehicles for industrial applications.
Earlier this year, Nova was a second-place award winner at the 2021 Tech.AD Europe Awards , in the category of Most Innovative Use of Artificial Intelligence & Machine Learning in the Development of Autonomous Vehicles & Respective Technologies.
“The key value proposition of the Nova lidar is its combination of a wide horizontal and vertical field of view, the very compact size, the low power consumption and an attractive volume price,” said Dr. Jun Pei, CEO of Cepton.
“With that, we hope to significantly enhance vehicle safety in everyday passenger cars by making Nova a mass-market lidar solution . In addition, it uses a scaled version of Cepton’s patented MMT architecture that is already in use in the long-range lidars that we are supplying in our major ADAS lidar program with our key OEM customer . We believe that this means that the core technology enabling Nova has reached a high maturity level and is licensable to manufacturing partners, especially automotive Tier 1s .”
Detailed information about the CES 2022 Innovation Awards honorees can be found at CES.tech/innovation . In January 2022, Cepton will join many other honorees in showcasing their products in the Innovation Awards Showcase area at CES 2022. At the Cepton Booth (#5518, LVCC – West Hall), Cepton will also showcase Nova alongside its comprehensive portfolio of lidar solutions for smart mobility , covering automotive and smart infrastructure applications . Please visit the Cepton website for more information.
About Cepton Technologies, Inc.
Cepton provides state-of-the-art, intelligent, lidar-based solutions for a range of markets such as automotive (ADAS/AV), smart cities , smart spaces and smart industrial applications. Cepton’s patented MMT®-based lidar technology enables reliable, scalable and cost-effective solutions that deliver long range, high resolution 3D perception for smart applications.
Founded in 2016 and led by industry veterans with over two decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions. Cepton is headquartered in San Jose, California, USA, with a presence in Germany, Canada, Japan, India and China, to serve a fast-growing global customer base. For more information, visit www.cepton.com and follow us on Twitter and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211111005540/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
The Estée Lauder Companies Appoints Madeleine Boyd as Senior Vice President, Global Brand Communications16.7.2026 22:22:00 CEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Madeleine Boyd as Senior Vice President, Global Brand Communications, effective July 20, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716738393/en/ Photo by Esteban La Tessa As part of the company’s continued efforts to strengthen how its brands better connect with consumers, Ms. Boyd will establish and lead a newly integrated Global Brand Communications team. In this role, she will ensure the company’s diverse portfolio is anchored by a cohesive enterprise communications strategy, while accelerating bold, consumer-first storytelling that drives earned media, cultural relevance, and brand desirability. She will also strengthen creator engagement, helping the company’s brands gain attention where culture is being shaped. Ms. Boyd brings extensive experience spanning brand strategy, communications, consumer engagement, and cultural insight
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom